UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients …,

The first patient has been dosed in a Phase 2a clinical study to assess the safety and efficacy of UBX1325 in a broader population of patients with DME, …, The first patient has been dosed in a Phase 2a clinical study to assess the safety and efficacy of UBX1325 in a broader population of patients with DME, …, Read More

Scroll to Top